Mercy BioAnalytics Raises $59 Million Series B to Advance Cancer Detection Platform
The funding will support commercialization of the company’s extracellular vesicle-based liquid biopsy tests, starting with ovarian cancer screening.
Read MorePosted by CLP Edit Staff | Sep 9, 2025 | Amplification Technologies |
The funding will support commercialization of the company’s extracellular vesicle-based liquid biopsy tests, starting with ovarian cancer screening.
Read MorePosted by CLP Edit Staff | Sep 4, 2025 | Analytical Software Systems |
The new platform integrates genomic and epigenomic data in a single long-read sequencing assay, providing high-resolution insights into chromatin structure, gene regulation, and disease mechanisms.
Read MorePosted by CLP Edit Staff | Sep 3, 2025 | Lung Cancer |
The test demonstrated higher baseline sensitivity for ctDNA detection compared to gene mutation-based testing in AstraZeneca’s NeoADAURA study.
Read MorePosted by CLP Edit Staff | Aug 29, 2025 | Uncategorized |
Study demonstrates OneBreath platform can diagnose and predict pneumonia onset in cardiac surgery patients through volatile organic compound detection.
Read MorePosted by CLP Edit Staff | Aug 28, 2025 | Analytical Software Systems |
The expansion adds compatibility with Roche’s VENTANA DP 200 and DP 600 scanners and makes AISight Dx the first digital pathology image management system cleared under the FDA’s Predetermined Change Control Plan.
Read More